RARβ2 stands as a critical guardian against the uncontrolled cell growth that defines cancer. While its silencing through DNA methylation and histone modification is a hallmark of many tumors, the reversible nature of these changes offers a unique therapeutic window. Continued research into the molecular triggers of RARβ2 may lead to more effective treatments that leverage the body’s own regulatory systems to combat disease.
RARβ2 functions as a "brake" on cell growth. When activated by its natural ligand, retinoic acid (a derivative of Vitamin A), it binds to specific regions of DNA to trigger the transcription of genes that tell the cell to stop dividing or to die if it is damaged. In healthy epithelial cells, such as those in the lungs or breasts, RARβ2 maintains tissue integrity by ensuring that cells differentiate correctly. J2 rar
Because the silencing of RARβ2 is often epigenetic rather than a permanent genetic mutation, it is potentially reversible. Researchers have explored using DNMT inhibitors and HDAC inhibitors to strip away the chemical blocks and "unlock" the gene. By reactivating RARβ2, it may be possible to restore the body's natural ability to suppress tumor growth, making it a promising focal point for future cancer therapies. RARβ2 stands as a critical guardian against the
CCL28-induced RARβ expression inhibits oral squamous cell ... - PMC RARβ2 functions as a "brake" on cell growth
The retinoic acid receptor beta 2 (RARβ2) is a member of the nuclear receptor superfamily that plays a vital role in regulating cell growth, differentiation, and programmed cell death (apoptosis). In many human cancers, the expression of this gene is lost or significantly reduced, which is a key step in the development of tumors. Understanding the mechanisms that silence RARβ2 is essential for developing new strategies to reactivate it and halt cancer progression.